This company has been marked as potentially delisted and may not be actively trading. Champions Oncology (CSBR) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrendsBuy This Stock CSBR vs. VECT, VALN, OPT, IMTX, CGEM, RLAY, MGTX, TRML, DNA, and MAZEShould you be buying Champions Oncology stock or one of its competitors? The main competitors of Champions Oncology include VectivBio (VECT), Valneva (VALN), Opthea (OPT), Immatics (IMTX), Cullinan Therapeutics (CGEM), Relay Therapeutics (RLAY), MeiraGTx (MGTX), Tourmaline Bio (TRML), Ginkgo Bioworks (DNA), and Maze Therapeutics (MAZE). These companies are all part of the "biological products, except diagnostic" industry. Champions Oncology vs. VectivBio Valneva Opthea Immatics Cullinan Therapeutics Relay Therapeutics MeiraGTx Tourmaline Bio Ginkgo Bioworks Maze Therapeutics VectivBio (NASDAQ:VECT) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk. Do analysts rate VECT or CSBR? Champions Oncology has a consensus price target of $12.00, suggesting a potential upside of 104.95%. Given Champions Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Champions Oncology is more favorable than VectivBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Champions Oncology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is VECT or CSBR more profitable? VectivBio has a net margin of 0.00% compared to Champions Oncology's net margin of -1.12%. Company Net Margins Return on Equity Return on Assets VectivBioN/A N/A N/A Champions Oncology -1.12%N/A -2.32% Does the MarketBeat Community prefer VECT or CSBR? Champions Oncology received 142 more outperform votes than VectivBio when rated by MarketBeat users. Likewise, 60.56% of users gave Champions Oncology an outperform vote while only 43.48% of users gave VectivBio an outperform vote. CompanyUnderperformOutperformVectivBioOutperform Votes1043.48% Underperform Votes1356.52% Champions OncologyOutperform Votes15260.56% Underperform Votes9939.44% Which has higher valuation & earnings, VECT or CSBR? Champions Oncology has higher revenue and earnings than VectivBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVectivBio$27.34M20.97-$93.74MN/AN/AChampions Oncology$50.15M1.61-$7.28M-$0.06-97.57 Which has more risk and volatility, VECT or CSBR? VectivBio has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Does the media favor VECT or CSBR? In the previous week, Champions Oncology had 1 more articles in the media than VectivBio. MarketBeat recorded 1 mentions for Champions Oncology and 0 mentions for VectivBio. Champions Oncology's average media sentiment score of 1.04 beat VectivBio's score of 0.00 indicating that Champions Oncology is being referred to more favorably in the news media. Company Overall Sentiment VectivBio Neutral Champions Oncology Positive Do insiders & institutionals believe in VECT or CSBR? 41.3% of Champions Oncology shares are held by institutional investors. 9.7% of VectivBio shares are held by insiders. Comparatively, 47.0% of Champions Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryChampions Oncology beats VectivBio on 12 of the 15 factors compared between the two stocks. Get Champions Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSBR vs. The Competition Export to ExcelMetricChampions OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$144.96M$2.97B$5.55B$8.05BDividend YieldN/A1.87%5.09%4.22%P/E Ratio-105.5730.5322.7318.81Price / Sales1.61500.45406.97107.57Price / CashN/A168.6838.1834.62Price / Book-41.823.226.814.34Net Income-$7.28M-$72.35M$3.22B$247.85M Champions Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSBRChampions Oncology3.9768 of 5 stars$5.86-39.5%$12.00+105.0%+26.7%$144.96M$50.15M-105.57143Positive NewsVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeVALNValneva2.5445 of 5 stars$6.63-2.4%$16.00+141.3%-17.0%$538.76M$169.58M-51.00700Upcoming EarningsGap DownOPTOpthea0.7928 of 5 stars$3.41+7.2%$1.33-60.9%+0.9%$524.84M$87,666.000.008News CoverageGap UpIMTXImmatics1.9262 of 5 stars$4.24-0.5%$16.67+293.1%-53.7%$515.37M$155.84M-6.42260News CoveragePositive NewsCGEMCullinan Therapeutics2.6365 of 5 stars$8.10+2.7%$34.80+329.6%-69.7%$473.96MN/A-2.8530Analyst RevisionPositive NewsRLAYRelay Therapeutics2.0014 of 5 stars$2.75+2.2%$18.36+567.8%-50.6%$466.19M$10.01M-1.05330News CoveragePositive NewsGap DownMGTXMeiraGTx4.4858 of 5 stars$5.65+4.4%$24.50+333.6%+45.5%$445.53M$33.28M-4.67300Upcoming EarningsShort Interest ↑News CoveragePositive NewsTRMLTourmaline Bio2.7165 of 5 stars$16.76+4.7%$45.20+169.7%+13.6%$430.48MN/A-5.9444Earnings ReportNews CoveragePositive NewsDNAGinkgo Bioworks0.6777 of 5 stars$7.35-6.4%$4.58-37.8%N/A$426.55M$227.04M-0.56640Upcoming EarningsNews CoverageGap UpMAZEMaze TherapeuticsN/A$9.13+8.6%$25.67+181.1%N/A$399.86M$167.50M0.00121 Related Companies and Tools Related Companies VECT Competitors VALN Competitors OPT Competitors IMTX Competitors CGEM Competitors RLAY Competitors MGTX Competitors TRML Competitors DNA Competitors MAZE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSBR) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Champions Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CSBR Stock Free CSBR Stock Alerts